

7. Write short notes on any *two* of the following :

15

- (a) Biological functions of cytokines in innate and adaptive immunity
- (b) ELISPOT assay and its applications in immunological research
- (c) Antigen processing and presentation via the endogenous (MHC I) pathway.



Roll No.

Total Pages : 04

755205

May 2026

M.Sc. (Biotechnology/Microbiology/Zoology)

(Second Semester)

Immunology (BTP-110-V)

Time : 3 Hours]

[Maximum Marks : 75

Note : It is compulsory to answer all the questions (1.5 marks each) of Part A in short. Answer any *four* questions from Part B in detail. Different sub-parts of a question are to be attempted adjacent to each other.

Part A

1. Define the following :

- (a) Toll-like receptors and their role in innate immunity 1.5
- (b) Haptens 1.5
- (c) Antibody avidity 1.5
- (d) Allelic exclusion 1.5

- (e) Significance of class switching by B-Cells 1.5
- (f) Superantigens 1.5
- (g) Immunofluorescence microscopy 1.5
- (h) Autoimmunity and Multiple sclerosis 1.5
- (i) Lymphokines 1.5
- (j) Murine monoclonal antibodies and their application. 1.5

Part B

- 2. (a) Discuss the role of bone marrow and thymus in lymphocyte development. Describe the significance of spleen, lymph nodes and MALT as secondary lymphoid organs. 10
- (b) Describe the structure of antibodies in detail. 5
- 3. (a) Discuss the coordination between B cells, T cells, MHC molecules and complement in adaptive immunity. 5

- (b) Describe T cell development in the thymus. Explain positive and negative selection and central tolerance. 10

- 4. Explain the mechanism of complement activation and fixation that includes C3 convertase formation, membrane attack complex (MAC) and regulation. 15
- 5. (a) Describe the principle and types of ELISA (direct, indirect, sandwich, competitive). 5
- (b) Define hypersensitivity and classify it according to Gell and Coombs. Explain Type I, II, III and IV hypersensitivity reactions with examples. 10
- 6. (a) Define Vaccines. Classify vaccines based on their composition and method of preparation including COVID-19 vaccines. 10
- (b) Describe the principle and steps involved in hybridoma technology for production of monoclonal antibodies. 5